PITTSBURGH, Sept. 26 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. will host an investor day following the completion of the Merck Generics acquisition. Pending the closing, the investor day will take place on Wednesday, October 3, 2007 in New York City. Robert J. Coury, Mylan’s Vice Chairman and Chief Executive Officer, and distinguished members of the executive team from Mylan, Merck Generics and Matrix Laboratories will provide a detailed financial and strategic review of the new Mylan.
The full day of presentations will be broadcast live via webcast beginning at 8:30 a.m. ET. The presentations are expected to conclude by 2:30 p.m. ET.
To access the live webcast and view the accompanying slide presentation, please go to Mylan’s website at http://www.mylan.com and click on the webcast icon at least 15 minutes before the presentation is scheduled to begin to register and download or install any necessary software. If you are unable to view the live webcast, please access http://www.mylan.com at any time within 30 days to view a replay of the webcast.
Mylan Laboratories Inc. is a leading pharmaceutical company with three principle subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products. For more information about Mylan, visit http://www.mylan.com.
Mylan Laboratories Inc.
CONTACT: Kris King of Mylan Laboratories Inc., +1-724-514-1800; or NinaDevlin, or Robin Gilliland of Brunswick Group, +1-212-333-3810, both forMylan Laboratories Inc.
Web site: http://www.mylan.com/
